Inebilizumab (2) – Uplizna®
Immunoglobulin G4-associated disease
Characteristics
| Start date | 15.03.2026 |
|---|---|
| Resolution | 03.09.2026 – active procedure |
| INN | Inebilizumab |
| Brand name | Uplizna® |
| Pharm. company | Amgen GmbH |
| G-BA Procedure ID | D-1306 |
| Therapeutic area | Other diseases |
| Reason for procedure | New therapeutic indication |
Associated procedures
| Inebilizumab (3) | Uplizna® | Amgen GmbH | Myasthenia gravis, AChR antibody-positive, MuSK antibody-positive | n.d. | active procedure | |
| Inebilizumab (2) | Uplizna® | Amgen GmbH | Immunoglobulin G4-associated disease | n.d. | active procedure | |
| Inebilizumab (1) | Uplizna® | Horizon Therapeutics GmbH | Neuromyelitis optica spectrum disorders, anti-aquaporin-4 IgG seropositive | 460–980 | 100% additional benefit not proven |
<< List of all resolutions